research Alopecia With Endocrine Therapies in Patients With Cancer
Endocrine therapies for cancer significantly increase the risk of hair loss.
Search
forLearn
0 / 0 results — no results
Research
5 / 100 results 
research Gender Differences in Skin Aging and the Changing Profile of the Sex Hormones with Age
The document concludes that there are still unknowns about the effectiveness, risks, and detection of performance-enhancing drugs, and doping remains a challenge.
research Remediation of Prostate-Related Disorders Using Polyphenols: Kolaviron and Quercetin in Perspective
Kolaviron and quercetin may help treat prostate issues.
research The PCPT Study
research First Report of 'Candidatus Phytoplasma Aurantifolia' Associated with the Invasive Weed Eclipta Prostrata in Taiwan
'Eclipta prostrata' plants in Taiwan are infected with 'Candidatus Phytoplasma aurantifolia'.
Community Join
5 / 55 resultscommunity So we’re just ok with taking a research chemical now?
The conversation discusses the use of RU58841, a non-FDA approved research chemical for hair loss, with mixed opinions on its safety and effectiveness. Some users are willing to try it as a last resort after other treatments like Minoxidil and Finasteride failed, while others express concerns about potential long-term side effects and lack of official research.
community Maintaining hair until Breezula without Fin
A 21-year-old male experienced side effects from topical finasteride and is seeking alternative treatments to maintain hair until Breezula is available. He is considering using minoxidil, Nizoral, micro-needling, and vitamin D supplementation, and may try CB or RU58841 if necessary.
community Anyone wanna try and interview the developers of RU?
The conversation discusses arranging an interview with the developers of RU58841 to clarify its safety and reasons for halted research, with some users expressing concerns about potential risks and others citing financial reasons for the discontinuation of studies. Specific treatments mentioned include RU58841, minoxidil, and finasteride.
community RU58841 vs Pyrilutamide (scientist opinion)
Hair loss treatments, specifically about the effectiveness of RU58841 compared to Pyrilutamide. Molecular weights and side effects were discussed in terms of efficacy and cost-effectiveness.
community The story of RU58841/PSK3841
by
Typical-Promise-3001
in Research/Science 1 year ago RU58841, an anti-androgenic compound, showed early promise for treating alopecia but faced challenges after its patent in 1997. Despite advancing to Phase II trials, safety concerns and financial struggles led Aventis to abandon its development. Proskelia, which later merged into ProStrakan, couldn't prioritize the drug, leading to its eventual stagnation and failure to reach the market.